Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1 | Zendy

Elena Riera | Zendy; María D. Maciá | Zendy; A. Mena | Zendy; Xavier Mulet | Zendy; José Luis Pérez | Zendy; Y Ge | Zendy; Antonio Oliver | Zendy

Open Access

Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1

Author(s) -

Elena Riera,

María D. Maciá,

A. Mena,

Xavier Mulet,

José Luis Pérez,

Y Ge,

Antonio Oliver

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq143

Subject(s) - pseudomonas aeruginosa , microbiology and biotechnology , ciprofloxacin , biofilm , ceftazidime , cystic fibrosis , biology , meropenem , strain (injury) , respiratory tract infections , antibiotic resistance , antibiotics , bacteria , respiratory system , genetics , anatomy

Biofilm growth, mucoid phenotype and proficient resistance development by hypermutable strains dramatically limit the efficacy of current therapies for Pseudomonas aeruginosa chronic respiratory infection (CRI) in cystic fibrosis (CF) patients. We evaluated the activity of the new cephalosporin CXA-101, ceftazidime, meropenem and ciprofloxacin against biofilms of wild-type PAO1 and its mucoid (mucA), hypermutable (mutS) and mucoid-hypermutable derivatives, and analysed the capacity of these strains to develop resistance during planktonic and biofilm growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research